InsiderClue
← All stocks

AtriCure, Inc.

ATRC Net selling
CIK 0001323885 #1900 in the set updated 17 Sep 2026
Bought (1 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (1 mo)
$1.35M
$608.69K on a plan · $0.00 straight out of an exercise
Sold at will
$746.17K
2 of 4 sales
Net
−$1.35M
−$746.17K against sales at will

By person

16 insiders · 4 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Privitera Salvatore
Chief Technical Officer
—
$608.69K (2) scheduled
−$608.69K
147,264
0.2895%
$7.98M
+41.6%
Dahlquist Karl S.
Chief Legal Officer
—
$458.10K (1)
−$458.10K
87,319
0.1717%
$4.73M
+69.0%
GROVES REGINA E
Director
—
$288.07K (1)
−$288.07K
34,546
0.0679%
$1.87M
+12.3%
CARREL MICHAEL H
President, CEO, & Director
—
—
—
774,434
1.52%
$41.99M
+18.6%
Seith Douglas J
Chief Operating Officer
—
—
—
229,867
0.4519%
$12.46M
+49.0%
Wirick Angela L
Chief Financial Officer
—
—
—
204,893
0.4028%
$11.11M
+47.3%
WHITE ROBERT S.
Director
—
—
—
128,318
0.2523%
$6.96M
+32.6%
Noznesky Justin J
Chief Mktg & Strategy Officer
—
—
—
100,219
0.1970%
$5.43M
+40.6%
Doraiswamy Vinayak
Chief Scientific Officer
—
—
—
86,511
0.1701%
$4.69M
+44.7%
JOHNSON B KRISTINE
Director
—
—
—
55,954
0.1100%
$3.03M
+26.0%
Yount Deborah Lee
Chief Human Resources Officer
—
—
—
45,578
0.0896%
$2.47M
+6.8%
WEHRWEIN SVEN
Director
—
—
—
40,518
0.0797%
$2.20M
+39.8%
Telman Deborah H
Director
—
—
—
28,328
0.0557%
$1.54M
+68.8%
Nachman Shlomo
Director
—
—
—
24,655
0.0485%
$1.34M
+88.1%
Prange Karen
Director
—
—
—
22,809
0.0448%
$1.24M
−4.7%
Yuen Maggie
Director
—
—
—
14,015
0.0276%
$759.89K
+56.2%

Individual transactions

2
Insider
Date
Role
Action
Shares
Price
Amount
Privitera Salvatore
8 Sep 2026
Chief Technical Officer
Sold on a plan
3,657
$55.00
$201.14K
Privitera Salvatore
2 Sep 2026
Chief Technical Officer
Sold on a plan
7,763
$52.50
$407.56K
Show all 4 transactions →

What was left out

Form 4 filings counted 4
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 2
Sales straight out of an exercise 0
Sales at will 2
Transactions with no price 0
Shares from compensation/vesting 0
History held since 14 Sep 2016